26
total announcements
GLENMARK.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹62,339 Cr
P/E (TTM)
34.7
P/E (Forward)
22.8
EPS (TTM)
₹63.69
52W Low
₹1,794.00
52W High
₹2,536.85
Dividend Yield
0.11%
Beta
0.25
Price / Book
5.9
Debt / Equity
5.6
Revenue (TTM)
₹17,737 Cr
Gross Margin
71.94%
Operating Margin
15.72%
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd has announced the record date for dividend for the Financial Year ended March 31, 2026 as August 31, 2026. The company has also approved the financial results for the quarter ended June 30, 2026 and announced the reconstitution of the Risk Management Committee.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹24,349.93 crore and profit before tax at ₹8,661.02 crore.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, with annual sales of approximately $1.6 billion in the 12-month period ending May 2026.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd has published a newspaper advertisement for the transfer of shares to the Investor Education and Protection Fund (IEPF) Authority, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd has announced an earnings call for its unaudited financial results for the quarter ended June 30, 2026, scheduled to be held on August 03, 2026. The call will cover the company's Q1 FY 2027 results.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd has received U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for children aged 6 to less than 12 years for the treatment of symptoms of Seasonal Allergic Rhinitis.